Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis. by Bacchetti, Peter et al.
UCSF
UC San Francisco Previously Published Works
Title
Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: 
non-Markov multistate model analysis.
Permalink
https://escholarship.org/uc/item/6741j98p
Journal
PloS one, 6(5)
ISSN
1932-6203
Authors
Bacchetti, Peter
Boylan, Ross
Astemborski, Jacquie
et al.
Publication Date
2011
DOI
10.1371/journal.pone.0020104
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Progression of Biopsy-Measured Liver Fibrosis in
Untreated Patients with Hepatitis C Infection: Non-
Markov Multistate Model Analysis
Peter Bacchetti1*, Ross Boylan1, Jacquie Astemborski2,3, Hui Shen4,5, Shruti H. Mehta3, David L.
Thomas2, Norah A. Terrault4,6, Alexander Monto4,5
1Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America, 2Department of Medicine,
Johns Hopkins University, Baltimore, Maryland, United States of America, 3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
Maryland, United States of America, 4Department of Medicine, University of California San Francisco, San Francisco, California, United States of America, 5Division of
Gastroenterology, San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America, 6Department of Surgery, University of California San
Francisco, San Francisco, California, United States of America
Abstract
Background: Fibrosis stages from liver biopsies reflect liver damage from hepatitis C infection, but analysis is challenging
due to their ordered but non-numeric nature, infrequent measurement, misclassification, and unknown infection times.
Methods: We used a non-Markov multistate model, accounting for misclassification, with multiple imputation of unknown
infection times, applied to 1062 participants of whom 159 had multiple biopsies. Odds ratios (OR) quantified the estimated
effects of covariates on progression risk at any given time.
Results: Models estimated that progression risk decreased the more time participants had already spent in the current
stage, African American race was protective (OR 0.75, 95% confidence interval 0.60 to 0.95, p = 0.018), and older current age
increased risk (OR 1.33 per decade, 95% confidence interval 1.15 to 1.54, p = 0.0002). When controlled for current age, older
age at infection did not appear to increase risk (OR 0.92 per decade, 95% confidence interval 0.47 to 1.79, p = 0.80). There
was a suggestion that co-infection with human immunodeficiency virus increased risk of progression in the era of highly
active antiretroviral treatment beginning in 1996 (OR 2.1, 95% confidence interval 0.97 to 4.4, p = 0.059). Other examined
risk factors may influence progression risk, but evidence for or against this was weak due to wide confidence intervals. The
main results were essentially unchanged using different assumed misclassification rates or imputation of age of infection.
Discussion: The analysis avoided problems inherent in simpler methods, supported the previously suspected protective
effect of African American race, and suggested that current age rather than age of infection increases risk. Decreasing risk of
progression with longer time already spent in a stage was also previously found for post-transplant progression. This could
reflect varying disease activity, with recent progression indicating active disease and high risk, while longer time already
spent in a stage indicates quiescent disease and low risk.
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Introduction
Chronic infection with hepatitis C virus (HCV) has been
estimated to affect 3.2 million persons in the United States and 130
million worldwide and is a leading cause of liver failure and the
need for liver transplant [1,2]. One way of assessing liver damage
known as fibrosis is to categorize liver biopsies into fibrosis stages
using established scales that range from no damage (stage 0) to
cirrhosis [3]. Although such fibrosis staging is widely used
clinically, statistical analysis of biopsy-measured fibrosis progres-
sion poses considerable challenges. First, the stages are ordered but
are not numeric, meaning that differences between consecutive
stages are not necessarily equivalent in any meaningful sense.
Second, biopsies are too invasive and expensive to perform
frequently. Many patients in research studies provide only one
observed stage. When multiple observations are available, they are
usually widely spaced (e.g., 5 years apart), and an observed
progression could have occurred at any time between biopsies,
which leaves the exact time of progression unknown. Third,
observed fibrosis stage is often misclassified, both because reading
of biopsy specimens is not perfectly standardized and because
biopsies may not accurately represent the overall state of the entire
liver [4]. Finally, most patients available for study have been
infected with HCV at some unknown time in the past, and the
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usual practice of imputing this time based on reported histories of
risk factors can be inaccurate [5].
Methods for multistate modeling [6,7], such as implemented in
the ‘‘msm’’ package for R (available at http://cran.r-project.org/
web/packages/msm/index.html), deal with many of these diffi-
culties and have been used to analyze fibrosis stage data [8,9], but
they make the strong simplifying assumption that previous history
of progression does not impact current risk of progression—the so-
called memoryless or Markov assumption. For HCV, however,
there is considerable interest in whether slow progression up to the
present predicts low risk of progression in the future. A new
method for multistate modeling without Markov assumptions was
recently applied to fibrosis progression following liver transplant
(where time of infection of the new liver is known). Here, we apply
that method [10] to data from chronically infected patients from
three studies, using multiple imputation [11] to account for
uncertainty about time of HCV infection.
Methods
Ethics Statement
We report here a secondary analysis of fully de-identified data,
including no dates more specific than calendar year. This was
approved by the University of California at San Francisco
Committee on Human Research. The original source studies
(see below) obtained written informed consent from participants to
have their data stored and analyzed for research purposes, and
they were approved by the University of California at San
Francisco Committee on Human Research and the Johns Hopkins
Bloomberg School of Public Health Review Board.
Objectives
We sought to assess the impact of potential risk factors on
fibrosis progression, while avoiding questionable assumptions and
accounting for fibrosis misclassification and uncertainty about
duration of HCV infection. Particular interest focused on how
history of progression up to a given time predicts current risk of
progression. Human immunodeficiency virus (HIV) infection [12],
African American race [9], and age [5] were predictor variables of
particular interest.
Data Sources
We report here new analyses of previously-collected data from
three studies: the AIDS Link to Intravenous Experience (ALIVE)
study [13,14,15]; the Hepatitis C and Alcohol Study (HALS)
[16]; and the San Francisco Veterans Affairs Medical Center
(SFVA) liver studies cohort [17]. For this analysis, we excluded
participants with chronic hepatitis B infection or hepatocellular
carcinoma, and we excluded biopsy results that were after
interferon treatment or liver transplant. The ALIVE study had
fibrosis staged on both the Metavir [18] and Ishak [19] scales; a
cross-tabulation of stages showed near-perfect correspondence of
Ishak 0 with Metavir 0, Ishak 1 or 2 with Metavir 1, Ishak 3 with
Metavir 2, Ishak 4 or 5 with Metavir 3, and Ishak 6 with Metavir
4 (cirrhosis). We used this correspondence to convert Ishak
scores in the HALS study to Metavir scores. SFVA participants
had biopsies staged from 0–4 using the Batts-Ludwig scale [20].
We treated this as equivalent to Metavir stages for analysis
purposes because both are 0 to 4 ratings with similar criteria for
each stage and because a study directly comparing the methods
on the same biopsies found exact agreement in 49 of 50 cases
[21]. All biopsies were obtained prospectively after study
enrollment. (A previous analysis of SFVA data [17] excluded
pre-1997 biopsies because they lacked the needed type of data on
alcohol use.)
Statistical methods
Model. To preserve the advantages of multistate modeling
while avoiding questionable Markov assumptions and allowing use
of covariates that change over time, we used a new method
implemented in the R package mspath, which is available at http://
cran.r-project.org/web/packages/mspath/index.html. Technical
details of this method have been described elsewhere [10]. The
method assumes the following outline of how disease progresses:
1. Each person starts at stage 0 at the time of HCV infection.
2. Time after infection is divided into discrete time steps (such as
age in years).
3. At each time step, the person either remains at the same stage
or progresses to the next higher stage.
4. The risk of progression at each time step is determined by the
progression history up to that point, along with covariates,
including current values of covariates that may have changed
over time (termed time-varying covariates).
The method considers for each person every specific history of
progression over time (or path) that could have produced the
observed fibrosis stage(s). For example, a person with an observed
stage of 2 at time step 5 could have 1) progressed to stage 1 at step
1, to stage 2 at step 3, stayed in stage 2 until step 5 and then been
accurately observed, or 2) progressed to stage 1 at step 2, to stage 2
at step 5 and then been accurately observed, or 3) progressed to
stage 1 at step 5 and then been misclassified as stage 2, and so on
(too many possibilities to list, even in this simple case). Models that
include effects of progression history up to a given point, and
effects of time-varying covariates, can be applied to each specific
path, and the likelihood of having observed the actual data is then
calculated by summing over all the possible specific paths.
Estimated covariate effects are obtained as those that maximize
the likelihood of the observed data, a standard statistical approach
to estimation. The influence of covariates on the probability of
progression to the next stage is modeled on the log-odds scale, so
we present estimated effects as odds ratios. We defined the time
scale as current age in years minus age in years at time of HCV
infection, and most models used time steps of 1.5 years (to keep
computational burden manageable). In a sensitivity analysis, we
re-estimated one model using 1-year time steps. We also excluded
biopsies occurring 40 or more years after HCV infection (again to
keep computational burden manageable).
Misclassification of stage. To account for the reality that
observed stage at a given time may differ from the person’s true
stage at that time, we included misclassification probabilities
in the models. For most models, we assumed the optimistic
misclassification probabilities shown in Table 1. These are from an
analysis of several studies specifically focused on misclassification of
fibrosis stage from liver biopsies [4]. In a sensitivity analysis, we also
re-estimated one model using the more pessimistic misclassification
probabilities in Table 1, which are also from the earlier analysis [4].
Predictors based on past progression history. We
investigated possible departures from the usual Markov
assumptions by assessing four predictor variables that the
mspath program defines for each step of each path, reflecting
progression history up to that point:
Time in stage—the amount of time already spent in the current
stage. A negative coefficient or odds ratio ,1 for this variable
indicates that risk of progression is less when a longer time has
already been spent in the stage without progressing; this might
Hepatitis C Progression
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occur if having recently progressed to the current stage tends to
indicate that disease is active, creating higher risk of continuing
progression, while having been in the stage a long time tends to
indicate quiescent disease and lower risk. A positive coefficient or
odds ratio .1 indicates that risk of progression is higher when a
longer time has already been spent in the current stage; this might
occur if underlying disease is steady and incremental so that it
eventually accumulates enough to manifest as progression to the
next stage.
Loge(c+time in stage), where c is a specified positive number that
prevents taking the logarithm of zero the first time a path is in a
new stage (we used c=half the step size in all analyses). This allows
a different shape for the influence of time in stage on progression
risk. Its qualitative interpretation is the same as noted above for
time in stage.
Total time in all previous stages—the amount of time that it
took to reach the current stage. A negative coefficient or odds ratio
,1 for this variable indicates that risk of progression is less if the
person has previously been progressing more slowly (took longer to
reach the current stage). A positive coefficient or odds ratio .1
would indicate that those previously progressing more slowly are
now at higher risk. (This variable is not used in modeling
progression from stage 0 to 1, because there are no previous
stages.)
Loge(c+total time in previous stages), where c is the specified
positive constant described above. This allows a different shape for
the influence of time in previous stages on progression risk.
Other predictors. We evaluated a number of other factors
that may influence fibrosis progression. The three studies selected
participants in different ways from different populations, so we
controlled for study in all models by including indicator variables
for ALIVE and for HALS. This was important for preventing
spurious apparent associations due to confounding with source
study. We allowed the effects of study to be stage-varying, i.e., to
differ for progression between different stages, because the
simplifying assumption that the effect was identical for all 4
transitions between stages did not fit the data nearly as well. Other
predictors were initially evaluated as having the same effect on all
transitions; they are listed below:
Sex—male compared to female.
Race/ethnicity—classified as Caucasian, African America,
Hispanic, and other. Because of previous findings concerning
African Americans, we also evaluated this as African American
compared to all other categories lumped together.
HIV—we determined coinfection with HIV at each time step,
based on age at HIV infection imputed as described in the next
section. Because treatment for HIV changed dramatically over
time [22], we also examined whether the effect of HIV differed in
different calendar periods: before 1996 versus 1996 and later; and
before 1996 versus1996–2000 versus after 2000.
Primary reported HCV infection risk factor—classified as
injection drug use for participants reporting any injection drug
use; otherwise, we classified it as receipt of blood transfusion or as
needlestick if those were reported. All others were lumped together
as ‘‘Other/none’’.
Tobacco smoking—collected only during study participation.
We classified this as yes or no based on any reported smoking, and
assumed that the earliest report also applied back to age 16.
Alcohol consumption—the HALS study collected a compre-
hensive alcohol consumption history, but the other studies only
provided information on recent consumption collected during
study participation. For each year of age of HALS participants, we
categorized alcohol consumption as ‘‘None’’ if the age was in a
period of reported alcohol abstinence, as ‘‘Moderate’’ if they
reported drinking less than 3 drinks per day on less than 20 days
per month or less than 5 drinks per day on less than 4 day per
month, or as ‘‘Heavy’’ otherwise. For the other two studies, we
approximated similar definitions using available data and assumed
that the earliest measures applied back to age 21. Because this is
likely to be inaccurate, primary analyses of alcohol only used
HALS participants.
Injection drug use—based on reported ages of first and last
injection drug use, we determined whether each participant was
using injection drugs at each time step.
Body mass index—this was defined as weight in kilograms
divided by the square of height in meters, which were only
collected during study participation. We assumed that the earliest
value also applied back to the age of HCV infection.
Current age—evaluated at each time step as a time-varying
covariate.
Age at HCV infection—evaluated as a fixed covariate, multiply
imputed as described in the next section.
Multiple imputation. We applied a strategy known as
multiple imputation [11], because exact values were generally
unavailable for age at HCV infection and age at HIV infection,
and some observations had missing data for alcohol consumption,
smoking, and body mass index. This approach is more valid than
assuming that infection occurred at the reported age of first risk
factor (which has typically been used for age at HCV infection [5])
or the common practice of simply deleting observations that have
a missing value for any covariate. For risk factor modeling, we
generated 5 data sets, each replacing missing covariates with
values randomly imputed from models built using the non-missing
data, along with imputed ages of HCV and HIV infection from
external analyses (see next paragraph). We then analyzed each and
combined the results of the 5 analyses using established methods to
obtain overall estimates and standard errors [11]. In some cases,
estimated log odds ratios in some or all imputed data sets were
effectively infinite, causing methods based on standard errors in
multiple imputation to break down. We therefore note likelihood
ratio p-values and profile likelihood confidence bounds for some
results. We use the term deviance to denote twice the negative log
likelihood, which is the quantity used in likelihood ratio tests; a
difference in deviance of 3.84 has p= 0.05 for comparing a base
model to one with one additional parameter.
We imputed 5 values of age at HCV infection for each
participant by putting their risk factor histories and age first known
to be infected into an external model of risk. The model has been
reported previously [5] and was based on reported injection drug
use history and other characteristics; it was built using data from
Table 1. Misclassification probabilities assumed for analyses.
Probability of Observed Stage Given True Stage
Optimistic* Pessimistic{
0 1 2 3 4 0 1 2 3 4
True Stage 0 0.81 0.19 0 0 0 0.74 0.26 0 0 0
1 0.07 0.73 0.19 0 0 0.24 0.54 0.22 0 0
2 0 0.10 0.80 0.09 0 0 0.19 0.65 0.16 0
3 0 0.03 0.23 0.67 0.07 0 0.10 0.45 0.37 0.08
4 0 0 0 0.08 0.92 0 0.01 0.07 0.25 0.67
*From Table 1, line 4 of reference [4].
{From Table 3 of reference [4].
doi:10.1371/journal.pone.0020104.t001
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4623 street-recruited injection drug users. As a sensitivity analysis,
we repeated some models using 5 imputed data sets based on a
model of HCV infection risk built by the same methods but using
data from 2248 mostly HIV-infected women [5]. The reference
[5] fully describes both models, includes figures illustrating the
effects of age and calendar time, and gives the exact code that we
used to obtain the fitted probabilities of infection at each age for
each person in a supplemental file at http://www.biomedcentral.
com/content/supplementary/1471-2334-7-145-s2.pdf. For pur-
poses of summarizing the available data, we also imputed one
additional value as the conditional mean of the probability
distribution of age at HCV infection given each participant’s first
age known infected and risk factors. We imputed age of HIV
infection using age first known to be infected and the estimated
distribution of numbers of infections among injection drug users
over calendar time from a national study [23], assuming no risk
before age 13 or before the year 1980. We then imputed other
missing predictors using the Markov-chain-Monte-Carlo method
in the Statistical Analysis System’s (SAS Institute, Cary, NC,
version 9.1.3) MI procedure, separately for each study, with all
available variables included in the process. To approximate the
recommended practice of including the outcome as one of the
variables used to impute missing predictors [24], we also included
a variable defined as the first observed fibrosis score divided by
years since imputed HCV infection.
Predictor selection. Because simultaneous inclusion of all
potential risk factors in a single model would not be computationally
feasible or statistically reliable, we sought to build a parsimonious
multivariate model that included risk factors that had the strongest
evidence for an influence on progression. We then examined the
effects of the remaining potential risk factors when added to this
model. Because of the high computational burden of our method,
we performed some preliminary exploration of models using the
additional single imputation based on conditional mean age of
HCV infection, but we found that this differed too much from
multiple imputation analyses using the 5 randomly imputed data
sets. We therefore used full multiple imputation for confirmation of
predictor selection. We included source study because it was a
potential confounder of other effects, and we included
log(0.75+years in stage) because it was of primary interest and
appeared to strongly influence progression risk. When added to a
model including stage-varying study effects and log(0.75+years in
stage), African American race (versus all others) appeared to be an
important predictor, based on the p-value and direction and
magnitude of the estimated effect. We therefore report this primary
model in detail, along with the estimated effects that other
predictors had when added to this model. We also evaluated
substituting each of the other 3 predictors based on progression
history for log(0.75+years in stage), and adding the time-in-previous-
stages predictors to the primary model.
Special handling of age variables. The estimated effects of
the two age variables listed above, current age at each time step
and age at HCV infection, may be subject to bias [5]. When the
imputed age of HCV infection is too early, this will make
progression look slower than it really was, inducing a spurious
protective effect of younger age at infection. When imputed age of
infection is too late, this will make progression look faster than it
really was, making older age at infection appear to increase risk,
which is the same spurious effect. Thus, any error in either
direction creates the same bias, and multiple imputation may not
do much to mitigate this problem. Little change in the estimated
effect was observed with multiple imputation in a previous study
[9]. For current age at each time step, the impact may be more
subtle because this variable is known rather than imputed with
some error. Bias may nevertheless occur because age at infection
determines which ages are assumed to be part of followup during
which progression could have occurred. A too-early imputation of
age at HCV infection will make progression look slower and cause
spurious inclusion of some younger current ages in the post-
infection followup time, while a too-late imputation will make
progression look faster and will cause only older current ages to be
included as post-infection. We therefore did not include current
age or age at HCV infection in the primary models evaluated as
described in the previous paragraph. We added each, and both, to
the primary model, and we also performed some simulations to
evaluate the potential bias. We used the primary fitted model
without age effects to generate simulated observations of fibrosis
stage, at the same times as the original observations, using an
additional independent set of imputed ages at HCV infection. We
did this independently for each of the 5 original imputed data sets,
generating 5 new simulated data sets with realistic amounts of
error in the imputed HCV infection ages and with no actual
association of current age or age at HCV infection with rate of
progression. We then fit the primary model plus current age and
the primary model plus age at HCV infection to the simulated
data; any apparent effects in these models are due to bias and
therefore provide some indication of how much bias may be
present. We then repeated the entire process using another
independently imputed set of assumed actual HCV infection ages.
Performing a large number of such simulations, however, would
not be computationally practical.
Results
Study participants
There were 1082 participants available for study, with 1284
biopsies. For 20 of them, their first biopsy was $40 years after
their mean predicted age of HCV infection. Because our limitation
of followup time to 39 years is likely to exclude these from most
imputed data sets, Tables 2 and 3 summarize characteristics of the
remaining 1062. The randomly imputed ages of HCV infection
are more variable than the means and therefore have more that
were long ago, so the 5 imputed data sets ranged from 1015 to
1027 participants included.
Progression model and risk factors
Our primary fitted progression model is described by Figure 1
and the top part of Table 4. The odds ratios for years in stage are
somewhat complicated to interpret. For example, for the 0 to 1
transition, the odds ratio of 0.39 implies that the estimated odds of
progressing drop by a factor of 0.39 if loge(0.75+years in stage)
increases by 1 unit, which means that (0.75+years in stage)
increases by a factor of e<2.72. This would be the case if years in
current stage increase from 1.5 to 5.4, for example. We use
Figure 1 to more simply illustrate the estimated baseline
progression risk by time step based on fitted intercept terms and
the odds ratios for loge(0.75+years in stage). We show the
pointwise averages of the fitted curves for the five imputed data
sets, because curves defined by average parameter values would be
distorted by instances of effectively infinite estimated parameters
for some of the imputed data sets. All the estimates had risk of
progression decreasing as time already spent in the stage increased.
From Table 4, we see that evidence for this phenomenon was
statistically significant for the stage 0 to 1 and 2 to 3 transitions.
The decrease had a large p-value for the 1 to 2 transition. The
overall strength of evidence is unclear for the 3 to 4 transition,
because two of the imputed data sets produced effectively infinite
estimates (risk drops to zero after progression has been avoided for
Hepatitis C Progression
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one step) with likelihood ratio p-values of 0.021 and 0.028. The
protective effect of African American race versus all other groups
was in the expected direction with a small p-value. Allowing
African American race to have different effects for the different
transitions did not produce a statistically significant improvement
in any of the 5 imputed data sets (all p$0.70); the estimates for all
transitions were protective and similar to the overall estimate
except for stage 3 to 4 (odds ratio 1.35, 95% confidence interval
0.35 to 5.2, p= 0.66).
Substituting the untransformed years in stage for loge(0.75+-
years in stage) produced similar models but with slightly worse
fits overall (deviance greater by 1.7 on average over the 5 data
sets). Substituting either variable based on total time in previous
stages produced worse fits (deviance worse by at least 17 for
every data set). When added to the primary model, longer time
in stage 0 appeared to greatly reduce progression risk for the
stage 1 to 2 transition, indicating the plausible phenomenon of
slower progression through stage 0 predicting slower progres-
sion through stage 1. The evidence for this was somewhat
stronger than shown in Table 4, because one of the imputed
data sets had odds ratio = 0 (a degenerate estimate) with a
likelihood ratio p-value ,0.0001. For the 2 to 3 and 3 to 4
transitions, the effect of total time spent in previous stages was
estimated to be in the opposite direction, but with wide
confidence intervals. For the 2 to 3 transition, the evidence
for increased risk with longer time spent previous stages is also
stronger than indicated in Table 4 because two of the five data
sets produced effectively infinite odds ratios, with likelihood
ratio p-values of 0.021 and 0.082.
Table 5 shows estimated effects of other potential predictors
when controlled for all the terms in the primary model. The effect
of African American race was slightly weaker versus Caucasians
than versus all others (Table 4). Coinfection with HIV appeared
only slightly risky overall, with a wide confidence interval that
included substantial increased risk. Allowing the effect of HIV to
change with the advent of widely available highly active anti-
retroviral therapy in 1996 [22] produced a much higher estimated
risk in this era, but this did not quite reach p,0.05; the estimated
effect of HIV before 1996 became very uncertain. Further
subdividing HIV effects by calendar time resulted in highly
uncertain estimates. The estimated effect of heavy alcohol
consumption was in the expected direction, but modest and not
statistically significant; the upper confidence bound, however,
allows for a fairly substantial increased risk.
Sensitivity analyses
Table 6 shows the main results of interest produced by
repeating the primary model from Table 4 with three alterations,
Table 2. Summary of time-related characteristics, by source study.
ALIVE N (% of 236) HALS N (% of 202) SFVA N (% of 624) Total N (% of 1062)
Age at HCV Infection* ,15 6 (2.5) 8 (4.0) 10 (1.6) 24 (2.3)
15–19 92 (39.0) 71 (35.2) 145 (23.2) 308 (29.0)
20–24 103 (43.6) 85 (42.1) 249 (39.9) 437 (41.2)
25–29 24 (10.2) 32 (15.8) 162 (26.0) 218 (20.5)
$30 11 (4.7) 6 (3.0) 58 (9.3) 75 (7.1)
Age at last biopsy ,30 2 (0.9) 6 (3.0) 2 (0.3) 10 (0.9)
30–39 33 (14.0) 33 (16.3) 36 (5.8) 102 (9.6)
40–49 141 (59.8) 102 (50.5) 198 (31.7) 441 (41.5)
50–59 57 (24.2) 58 (28.7) 335 (53.7) 450 (42.4)
$60 3 (1.3) 3 (1.5) 53 (8.5) 59 (5.6)
Year of HCV infection* Pre-1966 0 (0.0) 3 (1.5) 12 (1.9) 15 (1.4)
1966–1970 42 (17.8) 28 (13.9) 156 (25.0) 226 (21.3)
1971–1975 66 (28.0) 50 (24.8) 230 (36.9) 346 (32.6)
1976–1980 65 (27.5) 60 (29.7) 162 (26.0) 287 (27.0)
1981–1990 59 (25.0) 56 (27.7) 60 (9.6) 175 (16.5)
After 1990 4 (1.7) 5 (2.5) 4 (0.6) 13 (1.2)
Year of last biopsy 1992–1995 0 00.00 11 (1.8) 11 (1.0)
1996–1999 83 (35.2) 2 (1.0) 134 (21.5) 219 (20.6)
2000–2003 82 (34.7) 189 (93.6) 290 (46.5) 561 (52.8)
2004–2008 71 (30.1) 11 (5.4) 189 (30.3) 271 (25.5)
Years, infection to last biopsy* ,20 49 (20.8) 39 (19.3) 38 (6.1) 126 (11.9)
20–24 60 (25.4) 56 (27.7) 125 (20.0) 241 (22.7)
25–29 69 (29.2) 58 (28.7) 212 (34.0) 339 (31.9)
30–34 43 (18.2) 40 (19.8) 173 (27.7) 256 (24.1)
35–39 15 (6.4) 9 (4.5) 76 (12.2) 100 (9.4)
*Based on single imputation of age at HCV infection (see text).
Abbreviations: ALIVE: AIDS Link to Intravenous Experience study [13,14,15]; HALS: Hepatitis C and Alcohol Study [16]; SFVA: San Francisco Veterans Affairs Medical
Center liver studies cohort [17]; HCV: hepatitis C virus.
doi:10.1371/journal.pone.0020104.t002
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as indicated in the body of the table. The key results, decreasing
risk with longer time already spent in a stage and the protective
effect of African American race, remain very similar. For the
case where age of HCV infection was imputed using a different
model, we also evaluated the estimated effects of HIV when
added to the primary model. The estimated effect of HIV at any
time remained similar (odds ratio 1.24, 95% confidence interval
0.84 to 1.83, p = 0.27), as did the estimated effect of HIV in the
year 1996 and later (odds ratio 1.98, 95% confidence interval
0.98 to 4.0, p = 0.058). Changing the time step to 1 year or using
the more pessimistic misclassification probabilities increased the
computational burden by 3- to 5-fold, to over a full day of
processing time per imputed data set in some cases. This made
more extensive sensitivity analyses and pursuit of likelihood ratio
p-values and profile likelihood confidence intervals too difficult
to be worthwhile, particularly given the reassuring initial
findings.
Evaluation of age effects
Table 7 shows the results of several analyses of age effects. Both
older current age at each time step and older age at HCV infection
showed strong evidence of increasing progression risk. When both
were included in the same model, however, current age appeared
to be the important factor. There was some collinearity between
the two, particularly for participants with shorter followup after
HCV infection, so the uncertainty in both estimated effects is large
in the model that includes both. This indicates that, in our data,
neither improves the fit to the data very much when added to the
model that already includes the other. Testing the linearity
assumption for current age by adding a quadratic term produced a
p-value of 0.27, indicating no strong evidence for non-linearity; the
estimated curvature was negative, indicating a slowing in the rate
of increased risk as age increases. Allowing the effect of current age
to differ for the different transitions between stages did not appear
to produce substantially improved fits to the data. The average
Table 3. Summary of other characteristics, by source study.
ALIVE N (% of 236) HALS N (% of 202) SF VA N (% of 624) Total N (% of 1062)
Sex Female 73 (30.9) 62 (30.7) 63 (10.1) 198 (18.6)
Male 163 (69.1) 140 (69.3) 561 (89.9) 864 (81.4)
Race/Ethnicity Missing 0 (0.0) 2 (1.0) 0 (0.0) 2 (0.2)
White 15 (6.4) 84 (41.6) 419 (67.2) 518 (48.8)
Black 215 (91.1) 60 (29.7) 134 (21.5) 409 (38.5)
Hispanic 5 (2.1) 37 (18.3) 38 (6.1) 80 (7.5)
Other 1 (0.4) 19 (9.4) 33 (5.3) 53 (5.0)
HIV-infected No 155 (65.7) 160 (79.2) 560 (89.7) 875 (82.4)
Yes 81 (34.3) 42 (20.8) 64 (10.3) 187 (17.6)
HCV risk factor Injection drug use 236 (100) 135 (66.8) 345 (55.3) 716 (67.4)
Transfusion 0 (0) 25 (12.4) 58 (9.3) 83 (7.8)
Needlestick 0 (0) 5 (2.5) 36 (5.8) 41 (3.9)
Other/none 0 (0) 37 (18.3) 185 (29.7) 222 (20.9)
Smoking Missing 0 (0.0) 0 (0.0) 190 (30.5) 190 (17.9)
No 20 (8.5) 73 (36.1) 54 (8.7) 147 (13.8)
Yes 216 (91.5) 129 (63.9) 380 (60.9) 725 (68.3)
Alcohol use* Missing 0 (0.0) 0 (0.0) 120 (19.2) 120 (11.3)
None 34 (14.4) 4 (2.0) 107 (17.2) 145 (13.7)
Moderate 47 (19.9) 20 (9.9) 36 (5.8) 103 (9.7)
Heavy 155 (65.7) 178 (88.1) 361 (57.9) 694 (65.4)
Body mass index (kg/m2)* Missing 95 (40.3) 15 (7.4) 211 (33.8) 321 (30.2)
,25 88 (37.3) 68 (33.7) 135 (21.6) 291 (27.4)
25–30 22 (9.3) 78 (38.6) 156 (25.0) 256 (24.1)
30 & up 31 (13.1) 41 (20.3) 122 (19.6) 194 (18.3)
Number of biopsies analyzed 1 130 (55.1) 202 (100) 571 (91.5) 903 (85.0)
per participant 2 65 (27.5) 0 (0) 53 (8.5) 118 (11.1)
3 41 (17.4) 0 (0) 0 (0.0) 41 (3.9)
Highest fibrosis stage observed 0 67 (28.4) 55 (27.2) 214 (34.3) 336 (31.6)
1 126 (53.4) 112 (55.5) 170 (27.2) 408 (38.4)
2 23 (9.8) 19 (9.4) 139 (22.3) 181 (17.0)
3 8 (3.4) 16 (7.9) 63 (10.1) 87 (8.2)
4 12 (5.1) 0 (0.0) 38 (6.1) 50 (4.7)
*Highest value in available data since imputed age of HCV infection.
Abbreviations: ALIVE: AIDS Link to Intravenous Experience study [13,14,15]; HALS: Hepatitis C and Alcohol Study [16]; SFVA: San Francisco Veterans Affairs Medical
Center liver studies cohort [17]; HIV: human immunodeficiency virus; HCV: hepatitis C virus.
doi:10.1371/journal.pone.0020104.t003
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improvement in the deviance was 4.6, which would not be unusual
by chance alone with the addition of 3 parameters (4 age effects
instead of one); one imputed data set had a likelihood ratio p-value
of 0.060, while the others were all $0.20. The estimated odds
ratios per 10 year increase in age were 1.17 for the stage 0 to 1
transition, 1.81 for the 1 to 2 transition, 0.98 for the 2 to 3
transition, and 1.75 for the 3 for 4 transition.
Because error in imputed ages at HCV infection could bias
estimated age effects as described in the Methods, we evaluated
the potential magnitude of such bias by analyzing simulated data
sets that had realistic amounts of error in age at HCV infection
and were generated from models with no actual age effects. Two
replicates of the process, shown in Table 7, had only small
estimated age effects, suggesting that most of the estimated effects
for the actual data are unlikely to be due to bias.
Discussion
We analyzed a substantial amount of data on fibrosis
progression using a new method that avoids many problems
inherent in other methods that have been used to analyze such
data. We found evidence that progression risk decreases after more
time has been spent in a stage, which concords with an analysis of
progression following liver transplant that used the same methods
[10]; methods previously used for analyzing fibrosis progression
cannot assess such effects. This finding may reflect a dynamic
nature of HCV infection, with recent progression indicating active
disease and a higher risk of further progression. Older age
increased progression, and this appeared to be driven by current
age rather than being a fixed effect of age at HCV infection (the
evidence for this is not conclusive, however, as shown by the wide
confidence intervals in the model in Table 7 that includes both age
effects). This also accorded with the previous analysis of post-
transplant progression, where progression increased with donor
age. Other previous analyses have also found an age effect [25] but
were limited by their methodology to evaluating presumed age at
HCV infection rather than current age; they also did not recognize
or assess potential bias [5]. A small simulation experiment
indicated that little of our observed age effect appeared to be
due to bias. We also found evidence for a protective effect of
African American race, which has previously been suspected [9].
There was a suggestion of increased risk due to HIV co-infection,
particularly in the era of effective anti-retroviral therapy beginning
in 1996. In prior years, HIV-infected potential participants who
experienced accelerated HCV progression may have also had
higher mortality from opportunistic infections, causing them to be
excluded from our source studies. There was also a suggestion that
slower progression through stage 0 tends to be followed by slower
progression through stage 1, but this did not hold for later
transitions between stages. A number of other factors may
influence progression, as some estimates in Table 5 may be large
enough to be important (e.g., male sex, heavy alcohol consump-
tion, and body mass index .30) and upper confidence bounds
generally are not low enough to provide strong evidence against
substantial increased risk.
The results here may seem to be less reliable than previous
studies of similar data because of the complex methods and
assumptions. The complexity, however, is inherent in the available
data and the disease process. Previous studies only appear to avoid
this by making strong simplifying assumptions that are implicit or
not given strong emphasis. Consider, for example, the simple
approach of obtaining a single fibrosis rate per year for each
person by dividing current observed stage by the time since
presumed infection [25]. This implicitly assumes that infection is
immediate at the reported time of first risk with no inaccuracy in
those reported times, fibrosis is never misclassified, each
progression between stages is numerically equivalent, and the
observed stage was just reached at the time of biopsy. Each of
these assumptions simplifies the statistical analysis and reduces the
apparent statistical variation in resulting estimates, but each is also
questionable or even known to be wrong. We have attempted to
deal realistically with these complexities. Notably, using multiple
imputation [11] to address the unknown ages at HCV infection
adds considerable complexity and results in wider confidence
intervals than would have been produced by pretending that ages
of HCV infection were all known, but this uncertainty really does
exist. We have also used multistate models, which better match
biopsy-based measurement of the disease process, and have
evaluated departures from the Markov assumptions usually used
in multistate modeling. We checked linearity and variation by
Figure 1. Baseline progression risk for the model in the top
part of Table 4, for a non-black participant in the San Francisco
Veterans Affairs Medical Center liver studies cohort [17]. (A)
Risk of progression at a time step of 1.5 years given no progression at
earlier time steps (hazard of progression). All transitions have
decreasing hazard, reflecting the odds ratios ,1 in Table 4 for years
in stage. For the transition from stage 2 to 3, the estimated hazard of
progression is 0.55 for the first step and 0 at all later times; this is not
shown to avoid compression of the vertical scale for the other
transitions. (b) Cumulative risk of progression. The cumulative risk in the
first time step is equal to the hazard; at later time steps, it is equal to the
previous cumulative risk plus the current hazard times (1 – previous
cumulative risk). The cumulative risk therefore increases by less than the
current hazard when the previous cumulative risk is already substantial.
doi:10.1371/journal.pone.0020104.g001
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stage for key predictors, and sensitivity analyses suggested that our
main results did not rely on the particular size of time step,
misclassification probabilities, or imputation model for age of
HCV infection. We believe that all these facts add credence to our
results.
Our methods permit analysis of time-varying covariates, which
was important for HIV and age. The distinction between current
age (time-varying) and age at HCV infection (fixed) may seem
subtle, but they could have different implications for the biology of
HCV disease and also for clinical prognosis. For example,
detecting recent progression to higher fibrosis could be cause for
alarm in an older patient even if original HCV infection was at a
very young age. This is the second infectious disease for which one
of us (PB) has found that careful consideration of both fixed and
time-varying age effects points to a different conclusion than only
considering fixed effects [26].
Limitations
Despite the specialized analyses and other strengths, this study
has a number of limitations. As for many other studies using liver
biopsies, selection bias is a potential concern. Restricting study to
clinic populations or those already known to be HCV infected can
create selection bias toward more rapid progression [27], and the
SFVA and HALS groups are clinic-based or partly clinic-based.
For ALIVE, there should be little selection bias, because
participants were selected from the community without respect
to HCV status, enrolled participants were tested for HCV, and a
random sample of those found to be chronically infected
underwent biopsy [14]. For all three studies, participants had to
agree to undergo liver biopsy in order to be included; this could
select for more severe disease if participants were more likely to
agree if they had symptoms. On the other hand, the unavoidable
restriction to participants who were alive at the time of recruitment
could tend to exclude more rapid progressors. Statistical methods
for dealing with this, known as left-truncation or late entry, are
available but would require a model that includes death from
fibrosis progression as an additional stage; calculations to deal with
late entry are also not available in the mspath software. Our
selection of only followup before treatment with interferon could
also tend to exclude more rapid progressors, although this may be
mitigated by the usual clinical desire to obtain a biopsy before
starting treatment. Selection bias may be most important for
estimation of overall rapidity of progression rates, which we have
not emphasized. For the estimated effects of risk factors to be
biased, selection for greater severity would have to differ according
to the levels of the risk factors. Because selection likely did differ
between source studies, we took steps to fully control for the effect
of study (see next paragraph).
Table 4. Primary progression model, and estimated effects of total time in previous stages when added to the primary model.
Odds 95% confidence interval
Predictor Transition Ratioa Lower Upper P-value
Loge(0.75+years in stage) 0 to 1b 0.39 0.23 0.65 0.0004
1 to 2 0.72 0.37 1.42 0.35
2 to 3c 0 0 0.84 0.028
3 to 4d 0.52 0.06 4.6 0.56
ALIVE study (vs SFVA study) 0 to 1 1.38 0.97 1.97 0.073
1 to 2 0.21 0.11 0.39 ,0.0001
2 to 3e 20.0 0.07 +‘ 0.30
3 to 4 4.3 0.92 20.4 0.063
HALS study (vs SFVA study) 0 to 1 1.66 1.12 2.4 0.011
1 to 2 0.16 0.09 0.30 ,0.0001
2 to 3f +‘
3 to 4f 0
African American (vs all others) All 0.75 0.60 0.95 0.018
Effects when added to above primary model
Years in all previous stages (per 1 year) 1 to 2g 0.16 0.02 1.05 0.056
(per 5 years) 2 to 3h 2.1 0.31 14.3 0.45
(per 5 years) 3 to 4 1.26 0.05 29.7 0.89
aOdds ratios indicate the estimated effects of the predictors on the risk of progression to the next stage at any given time step. Odds ratios below 1.0 indicate lowered
risk; ratios above 1.0 indicate increased risk.Based on 4 imputed data sets; the fifth had estimated odds ratio (OR) = 0 with likelihood ratio (LR) p-value ,0.0001.
bBased on 4 imputed data sets; the fifth had estimated odds ratio (OR) = 0 with LR p-value ,0.0001.
cAll imputed data sets had estimated OR= 0; the largest of the 5 LR p-values and the corresponding profile likelihood confidence bound are shown.
dBased on 3 imputed data sets; the other two estimated odds ratios were 0.13 and 0.15 with LR p-values of 0.028 and 0.021, but these were close to degenerate, with
much larger estimated standard errors and deviance nearly identical at OR = 0.
eAlthough the estimated OR was finite, the estimates in all 5 imputed data sets appeared to be nearly degenerate, with large standard errors and deviance at OR= +‘
nearly as good as at the finite estimated values.
fEstimates in all 5 imputed data sets were degenerate. As these are not parameters of interest, we did not pursue LR p-values or profile likelihood confidence bounds.
gBased on 4 imputed data sets; the fifth had estimated OR= 0 with likelihood ratio p-value ,0.0001.
hBased on 3 imputed data sets; the other two had estimated OR=+‘ with LR p-values 0.021 and 0.082.
Abbreviations: ALIVE: AIDS Link to Intravenous Experience study [13,14,15]; HALS: Hepatitis C and Alcohol Study [16]; SFVA: San Francisco Veterans Affairs Medical
Center liver studies cohort [17].
doi:10.1371/journal.pone.0020104.t004
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The distribution of biopsy-measured fibrosis was heterogeneous
across source studies. The strong influence of source study, and its
variation by stage, likely result from non-biological influences.
Differing misclassification of fibrosis due to differing readings of
biopsies is one important possibility, but differing selection of
participants is also likely to contribute to the study effects. For
example, it is unlikely that the true rate of stage 4 (cirrhosis) was
really the same in HALS as in the other studies; this would imply
that about 10 biopsies showing cirrhosis were all misread in
HALS. Because the studies were drawn from differing populations
by differing methods, selection effects are bound to differ between
them. The proportions of biopsies from different calendar time
periods also differed between studies. The imputation models for
age at HCV infection accounted for strong influences of calendar
time [5]; changes over time in progression rates may also be
possible, but seem less likely with our focus on pre-treatment
biopsies only. We minimized the potential for source study to
confound other associations by fully controlling for its influence on
every transition, using a full contingent of 8 parameters for study
effects. This reduced the potential influence of selection bias on
other estimates, but it also added complexity to the models and
may have reduced the precision of other estimates. Using fewer
parameters did not seem viable, because differences between the
studies varied by stage, and because any oversimplification of
study effects could increase concern about selection bias and
confounding.
We accounted for possible misclassification of biopsy-measured
fibrosis by factoring external estimates of misclassification rates
into the estimation process. This increases the statistical uncer-
tainty in our results, but rightly so. Along with multiple rather than
single imputation of age at HCV infection, this results in a better
assessment of precision and is a strength of this analysis. In
addition, a sensitivity analysis showed that our main findings were
insensitive to the exact misclassification assumptions. Nevertheless,
an ideal approach would utilize information on biopsy quality to
provide a customized matrix of misclassification probabilities for
each biopsy. Unfortunately, we did not have such refined estimates
available. Some multistate modeling methods, including the one
used here, can estimate misclassification probabilities as part of the
modeling process. This, however, would be computationally very
challenging and seems likely to be less accurate than estimates
from studies that were focused specifically on misclassification and
therefore employed multiple readings of the same biopsy or
multiple biopsies of the same liver. We have therefore used the best
estimates from such studies that we could obtain [4]. The median
(interquartile range) biopsy length was 19mm (14–24) in HALS
and 12 mm (9–19) in ALIVE, which are comparable to those in
the studies used to estimate misclassification [4]. (Biopsy length
was not available for the SFVA study.)
We assumed no backward transitions to lower stages; our
restriction to pre-treatment biopsies may make this assumption
reasonable, and no participants had spontaneously cleared HCV
infection at the time of any biopsy. This assumption implies that
any apparent backward transitions must be ascribed to misclas-
sification of at least one of the biopsies. Among the 159
participants with two or three biopsies, 21% had nominal
Table 5. Estimated effects of each other predictor when added singly to the primary model from Table 4.
Odds 95% confidence interval
Predictor Value Ratio Lower Upper P-value
Sex Male 1.21 0.94 1.57 0.14
Race/ethnicitya African American 0.79 0.62 1.01 0.055
(vs Caucasian) Hispanic 1.26 0.91 1.75 0.17
Other 1.23 0.85 1.79 0.27
HIV-infectedb Yes 1.17 0.64 2.1 0.61
HIV-infected, by treatment erab to 1995 0.68 0.17 2.7 0.58
(vs uninfected) 1996 on 2.1 0.97 4.4 0.059
HIV-infected, by treatment erab to 1995 0.37 0.00 568 0.79
(vs uninfected) 1996–1999 3.0 0.57 16.1 0.19
2000 on 1.49 0.34 6.6 0.60
Reported HCV risk factor Transfusion 0.99 0.72 1.37 0.96
(vs injection drug use) Needlestick 0.88 0.61 1.28 0.50
Other/None 1.21 0.96 1.53 0.11
Smoking Yes 1.07 0.83 1.40 0.59
Alcohol consumptionb,c Moderate 0.99 0.52 1.88 0.99
(vs none) Heavy 1.16 0.72 1.89 0.54
Injection drug useb Yes 0.92 0.69 1.23 0.58
Body Mass Index per 5 Kg/m2 1.05 0.97 1.14 0.24
Body Mass Index 25–30 1.09 0.88 1.36 0.42
(vs ,25) .30 1.19 0.95 1.50 0.14
aThis is an alternative finer breakdown instead of an addition to the primary model.
bThese are time-varying covariates, with potentially differing values at each time step.
cThis model was fitted on HALS participants only, because other studies lacked complete histories.
Abbreviations: HIV: human immunodeficiency virus; HCV: hepatitis C virus; HALS: Hepatitis C and Alcohol Study [16].
doi:10.1371/journal.pone.0020104.t005
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backward transitions of one stage and 3% of two stages, rates that
seem to be readily explainable by the substantial misclassification
probabilities previously estimated [4]. The progression model
could in principle be extended to allow backward transitions, and
the mspath software allows any specification of what transitions
are possible. Unfortunately, allowing backward transitions would
vastly increase the number of possible paths to be evaluated,
making computations infeasible. In addition, parameters govern-
Table 6. Results of sensitivity analyses for the primary model from Table 4 on predictors of interest.
Odds 95% confidence interval
Predictor Transition Ratio Lower Upper P-value
One-year time steps instead of 1.5 year-time steps
Loge(0.75+years in stage) 0 to 1a 0.40 0.25 0.66 0.0003
1 to 2 0.77 0.40 1.47 0.42
2 to 3b 0
3 to 4c 0.51 0.09 2.90 0.44
African American (vs all others) All 0.76 0.60 0.96 0.019
Pessimistic misclassification probabilities instead of optimistic, from Table 1
Loge(0.75+years in stage) 0 to 1a 0.26 0.06 1.20 0.084
1 to 2 0.77 0.37 1.59 0.48
2 to 3b 0
3 to 4d 0
African American (vs all others) All 0.71 0.53 0.95 0.020
Age of HCV infection imputed from alternative model
Loge(0.75+years in stage) 0 to 1c 0.37 0.22 0.63 0.0003
1 to 2 0.70 0.40 1.21 0.20
2 to 3b 0
3 to 4e 0.46 0.06 3.46 0.45
African American (vs all others) All 0.77 0.63 0.94 0.011
aBased on 4 imputed data sets; the fifth had estimated odds ratio (OR) = 0.
bAll imputed data sets had estimated OR= 0.
cBased on all 5 imputed data sets; none had estimated OR= 0.
dThree of the imputed data sets had estimated OR=0, precluding meaningful combination of just the remaining 2.
eBased on 4 imputed data sets; the fifth had a nearly degenerate estimated OR= 0.09 with an effectively infinite standard error, precluding synthesis with the others.
Abbreviations: HCV: hepatitis C virus.
doi:10.1371/journal.pone.0020104.t006
Table 7. Estimated effects of age when added to the primary model from Table 4, for the original data and for simulated data with
no age effects.
Odds 95% confidence interval
Predictor(s)a Value Ratio Lower Upper P-value
Models of the original, actual data
Current age at each time step Per 10 years 1.33 1.15 1.54 0.0002
Age at HCV infection Per 10 years 1.31 1.13 1.52 0.0003
Current age at each time step Per 10 years 1.45 0.74 2.8 0.28
Age at HCV infection Per 10 years 0.92 0.47 1.79 0.80
Models of simulated data with no actual age effects
Current age at each time step Per 10 years 1.08 0.88 1.31 0.46
Age at HCV infection Per 10 years 1.07 0.90 1.27 0.45
Replication on another independently simulated set of data with no actual age effects
Current age at each time step Per 10 years 1.03 0.87 1.22 0.74
Age at HCV infection Per 10 years 1.02 0.87 1.20 0.77
aResults separated by vertical space are from separate models; one model included both current age and age at HCV infection.
Abbreviations: HCV: hepatitis C virus.
doi:10.1371/journal.pone.0020104.t007
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ing the four additional transitions would have to be added, and
factors influencing regression could differ from those for
progression, substantially complicating the modeling. We therefore
cannot evaluate the effect of allowing backward transitions on our
results, but we believe that excluding them is close enough to
reality that it is unlikely to introduce serious bias.
A reviewer pointed out a potential bias that could impact our
estimated effects of years in prior stages, at the bottom of Table 4.
For example, if a participant were known to have reached stage 2
by a given time, with an unknown time of transition from stage 0
to 1, then a shorter time in stage 0 would mean a longer time in
stage 1 before progressing to stage 2, while a longer time in stage
zero would mean a shorter time in stage 1 before progressing to
stage 2. Either way would contribute to an apparent effect of
longer time in stage 0 increasing risk of progression from stage 1 to
2. Fortunately, we observed the opposite of what this bias would
produce, instead estimating a protective effect of longer time in stage
zero. Thus, the possibility of this bias only strengthens the evidence
for this effect. For the 2 to 3 and 3 to 4 transitions, we did estimate
increases in risk such as this bias would produce. This bias is
directly analogous to the potential bias in the estimated effect of
age at infection that we described, with time in previous stages
playing the role of time before (i.e., age at) HCV infection, so a
similar simulation-based investigation could be undertaken. We do
not consider this to be worthwhile, however, because the issue is
largely overshadowed by the very wide confidence intervals for
these effects.
Most of our participants had only one biopsy, which made them
less informative for estimation of the effects of years in current
stage and years in previous stages. Fortunately, we had enough
with multiple biopsies (15%) to obtain some useful estimates,
notably the protective effects of years in current stage in Table 4
for the 0 to 1 and 2 to 3 transitions. We also had relatively few
participants with advanced fibrosis, which is reflected in extreme
estimates or wide confidence intervals for most estimated effects
that are specific to the 2 to 3 transition and the 3 to 4 transition.
Some predictors may have been inaccurately measured, due to
reliance on self-report and extrapolation of study values to the
entire period of HCV infection, and some were missing for a
considerable proportion of participants. We did not analyze HCV
genotype or viral load as predictors, and complete history of
alcohol consumption was only available in the HALS study. We
did not evaluate the influence of measured immune status and
antiretroviral treatment history directly for HIV-infected partici-
pants. This would be very complicated and could be distorted by
self-selection of treatment and incomplete histories; we investigat-
ed differing HIV effects over calendar time as a feasible
alternative. Our statistical methods model progression over the
entire period of HCV infection, so we could not evaluate factors
such as inflammation and steatosis grade that are known only at
the time biopsy; these would have to be known at all times and
treated as time-varying covariates, but are unlikely to have
remained constant since infection. Our assumptions concerning
fibrosis misclassification and our model for imputing age of HCV
infection could be inaccurate, but sensitivity analyses using
alternatives showed similar results. All of our fitted models had
some parameters estimated to be effectively infinite. These could
not be used in standard methods for multiple imputation analysis,
so we used only the finite estimates and reported the infinite
estimates separately. In some cases, standard errors for other
parameters had to be obtained by re-estimating models with the
effectively infinite parameters held fixed; those standard errors did
not appear to differ substantially from the cases where standard
errors were available despite estimation of some effectively infinite
parameters. Finally, the computational burden of the method we
used is substantial. We were only able to complete our analyses
within about a month by often running 20 or more analyses
simultaneously using a specialized parallel computing facility.
Further Research
Ideally, prospective followup of persons known to be recently
infected with HCV would prevent selection biases and maximize
the value of information obtained from biopsies. Performing such
studies, however, might be difficult and expensive. Steps to
minimize misclassification (e.g., using multiple readings of each
biopsy) could also make data more informative and potentially
reduce the computational burden of our methods (if some
misclassifications become impossible). The methods used here
might provide more credible results and additional insights if
applied to larger data sets with more repeat biopsies. Computa-
tional feasibility is a potential issue, but will improve with time.
The non-Markov multistate modeling software that we used is
freely available at http://cran.r-project.org/web/packages/
mspath/index.html.
An appealing alternative to biopsy is non-invasive measurement
of fibrosis via imaging or biochemical analysis of peripheral blood
samples [28,29]. Some methods may already be as accurate as
biopsy, but evaluation of alternatives has suffered from inappro-
priate use of biopsy as a gold standard [30]. Studies with frequent
non-invasive measurements could be less dependent on imper-
fectly known times of HCV infection, because they could better
focus on observed trajectories. Evaluating how recent changes in
non-invasive measures predict subsequent change would permit
exploration of the phenomenon we found of decreasing progres-
sion risk with longer times already spent in a stage. If the
invasiveness, risk [31], and expense of biopsy curtails its use in
HCV research, the methods used here may still be useful for
analysis of data for other diseases that progress through stages.
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